Payment overview · 2025
General Payments
$328.82
15 reported records · 7 companies
Healthcare provider profile · identity verified
Joseph Durandis
Allopathic & Osteopathic Physicians|General Practice · MIAMI, FL · NPI 1396038766
Verified facts
What the public records show
CMS Open Payments records show Joseph Durandis received $328.82 in general payments during 2025 across 15 reported records.
ViiV Healthcare Company accounted for 49.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Dovato.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Eliquis by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $163.25 | 49.6% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $52.06 | 15.8% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $49.99 | 15.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.67 | 5.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.37 | 5.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.98 | 4.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.50 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $328.82 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $97.22 | 4 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $66.03 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $52.06 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| DOVATO dovato |
2025 | Dovato | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
135 | 24 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 615 | 188 |
| Amlodipine Besylate | Amlodipine Besylate | 481 | 135 |
| Metformin Hcl | Metformin Hcl | 334 | 97 |
| Gabapentin | Gabapentin | 205 | 52 |
| Losartan Potassium | Losartan Potassium | 197 | 56 |
| Lisinopril | Lisinopril | 187 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 184 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 177 | 66 |
| Meloxicam | Meloxicam | 155 | 40 |
| Spironolactone | Spironolactone | 149 | 53 |
| Nifedipine Er | Nifedipine | 147 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 146 | 56 |
| Eliquis | Apixaban | 135 | 24 |
| Furosemide | Furosemide | 133 | 39 |
| Carvedilol | Carvedilol | 115 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 41 |
| Famotidine | Famotidine | 99 | 33 |
| Xarelto | Rivaroxaban | 98 | 14 |
| Levetiracetam | Levetiracetam | 93 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 27 |
| Trazodone Hcl | Trazodone Hcl | 84 | 23 |
| Glipizide | Glipizide | 83 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 24 |
| Jardiance | Empagliflozin | 82 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 28 |
| Fetroja | Cefiderocol Sulfate Tosylate | 81 | suppressed |
| Latanoprost | Latanoprost | 74 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 24 |
| Allopurinol | Allopurinol | 71 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 65 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 19 |
| Farxiga | Dapagliflozin Propanediol | 61 | 18 |
| Tradjenta | Linagliptin | 60 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 59 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 59 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 57 | 14 |
| Januvia | Sitagliptin Phosphate | 53 | 20 |
| Baclofen | Baclofen | 52 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 26 |
| Simvastatin | Simvastatin | 51 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 16 |
| Timolol Maleate | Timolol Maleate | 50 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 49 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 24 |
| Mirtazapine | Mirtazapine | 47 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 19 |
| Azithromycin | Azithromycin | 45 | 30 |
| Celecoxib | Celecoxib | 43 | 14 |
| Glimepiride | Glimepiride | 43 | 11 |
| Labetalol Hcl | Labetalol Hcl | 42 | 16 |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 40 | suppressed |
| Levofloxacin | Levofloxacin | 40 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 14 |
| Omeprazole | Omeprazole | 38 | 13 |
| Finasteride | Finasteride | 37 | 11 |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 34 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 31 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 18 |
| Bumetanide | Bumetanide | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | 11 |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | 15 |
| Lactulose | Lactulose | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 26 | 12 |
| Sevelamer Carbonate | Sevelamer Carbonate | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Tivicay | Dolutegravir Sodium | 21 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Calcium Acetate | Calcium Acetate | 17 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 17 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $328.82 · 15 records | ViiV Healthcare Company | APRETUDE, DOVATO, Kerendia, MOUNJARO, PAXLOVID, QULIPTA, REPATHA, UBRELVY, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Dovato play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error